ABIVAX (EPA:ABVX) | WebDisclosure

PRESS RELEASE

published on 07/25/2025 at 08:00, 1 year ago

Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplémentaires des teneurs de livre associés, portant le produit brut de l'Offre à 747,5 M$ (637,5 M€)
Abivax a exercé intégralement l’option de souscription d’ADS supplémentaires, portant le produit brut de l'Offre à 747,5 M$ (637,5 M€), soutenant le développement de thérapies pour maladies inflammatoires

Biotechnologie Abivax Maladies Inflammatoires Souscription Produit Brut
PRESS RELEASE

published on 07/25/2025 at 08:00, 1 year ago

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Abivax announces full exercise of underwriters’ option to purchase additional ADSs, bringing gross proceeds of offering to $747.5M (€637.5M). Company to apply net proceeds to identified use of funds

Abivax Underwriters ADSs Offering Proceeds
BRIEF

published on 07/24/2025 at 14:45, 1 year ago

Abivax's $650M Public Offering of ADS

Biotechnology Abivax Capital Increase Public Offering Ads
BRIEF

published on 07/24/2025 at 14:45, 1 year ago

Abivax lance une offre publique d'ADS de 650 millions de dollars

Biotechnologie Abivax Augmentation De Capital Offre Publique PUBLICITÉS
PRESS RELEASE

published on 07/24/2025 at 14:40, 1 year ago

Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris. La société de biotechnologie se concentre sur le développement de traitements thérapeutiques pour les maladies inflammatoires chroniques

Euronext Paris Biotechnologie Abivax Traitements Thérapeutiques Maladies Inflammatoires
PRESS RELEASE

published on 07/24/2025 at 14:40, 1 year ago

Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) d’American Depositary Shares
Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) d’American Depositary Shares pour financer le développement de thérapies biotechnologiques. Details de l'offre, stabilisation et prévisions financières

Biotechnologie Abivax Ads Offre Publique Modalités Définitives
PRESS RELEASE

published on 07/24/2025 at 14:40, 1 year ago

Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax announces the trading resumption of its ordinary shares on Euronext Paris after a temporary halt for a public offering confirmation and pricing announcement

Euronext Paris Abivax Public Offering Clinical-stage Biotechnology Trading Resumption
PRESS RELEASE

published on 07/24/2025 at 14:40, 1 year ago

Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris. La société de biotechnologie se concentre sur le développement de traitements pour les maladies inflammatoires chroniques

Euronext Paris Biotechnologie Abivax Négociations Traitements
PRESS RELEASE

published on 07/24/2025 at 14:40, 1 year ago

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
Abivax announces pricing of $650M (€554M) public offering of American Depositary Shares to fund clinical development and working capital, with expected closing on July 28, 2025

Abivax Clinical Development Public Offering Pricing Closing
PRESS RELEASE

published on 07/24/2025 at 14:40, 1 year ago

Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) d’American Depositary Shares
Abivax annonce les modalités de son offre de 650M$ d'American Depositary Shares pour financer des développements cliniques. Stabilisation et options incluses

Abivax Développement Clinique Offre Publique Stabilisation American Depositary Shares

Published on 08/07/2026 at 00:45, 12 hours 7 minutes ago

NXT Energy Solutions Announces Second Quarter 2026 Results
Published on 08/06/2026 at 23:15, 13 hours 37 minutes ago

LNG Energy Group Announces Issuance of Second Partial Revocation Order and Further Details on Private Placement Financing
Published on 08/06/2026 at 22:15, 14 hours 37 minutes ago

Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada
Published on 08/06/2026 at 22:05, 14 hours 47 minutes ago

Innodata Reports Record Second Quarter 2026 Results
Published on 08/06/2026 at 22:00, 14 hours 52 minutes ago

Gold Terra Announces Closing of Second Tranche of the C$10.8M LIFE

View all ACCESSWIRE

Published on 08/07/2026 at 12:05, 46 minutes ago

Genel Energy PLC: Response to announcement made by DNO ASA
Published on 08/07/2026 at 11:12, 1 hour 40 minutes ago

EQS-Adhoc: Asklepios Kliniken GmbH & Co. KGaA submits request for the implementation of a squeeze-out of the minority shareholders of RHÖN-Klinikum Aktiengesellschaft
Published on 08/07/2026 at 11:00, 1 hour 52 minutes ago

MuniFin Group’s Half Year Report January–June 2026 is published
Published on 08/07/2026 at 11:00, 1 hour 52 minutes ago

PWO Group generates new business of EUR 363m and increases free cash flow in the first half of 2026
Published on 08/07/2026 at 10:45, 2 hours 7 minutes ago

Coolita launches Indonesia's first FAST Media Alliance with leading broadcasters

View all EQS

Published on 08/07/2026 at 08:30, 4 hours 22 minutes ago

Disclosure of shares outstanding and voting rights - 07.08.2026
Published on 08/07/2026 at 08:30, 4 hours 22 minutes ago

Déclaration nombre d'actions et droits de vote - 07.08.2026
Published on 08/06/2026 at 18:26, 18 hours 26 minutes ago

Air Liquide voting rights as of July 31st 2026
Published on 08/06/2026 at 18:26, 18 hours 26 minutes ago

Air Liquide droits de vote au 31 juillet 2026
Published on 08/06/2026 at 17:46, 19 hours 6 minutes ago

Déclaration des droits de vote à fin juillet 2026

View all LES ECHOS COMFI WIRE

News